Search
lenalidomide (Revlimid)/rituximab (Rituxan) (R2)
Indications:
- first line therapy for advanced follicular lymphoma
General
antineoplastic combination (combination chemotherapy)
References
- Ingram I
Ditching Chemo Appears Viable in Frontline Follicular Lymphoma.
PFS 'nearly identical' at 3 years with novel immunomodulatory
combination.
MedPage Today. June 06, 2018
https://www.medpagetoday.com/meetingcoverage/asco/73327
- Fowler NH, et al
RELEVANCE: Phase III randomized study of lenalidomide plus
rituximab (R2) versus chemotherapy plus rituximab, followed
by rituximab maintenance, in patients with previously untreated
follicular lymphoma.
American Society of Clinical Oncology (ASCO) 2018;
Abstract 7500.